News & Updates
Filter by Specialty:
NADIM II suggests PFS, OS benefits of nivolumab + chemo in resectable NSCLC
Adding nivolumab to paclitaxel-carboplatin chemotherapy in the neoadjuvant setting boosted progression-free survival (PFS) and overall survival (OS) in patients with resectable stage IIIA–B non-small cell lung cancer (NSCLC), according to results of the phase II NADIM II trial from Spain.
NADIM II suggests PFS, OS benefits of nivolumab + chemo in resectable NSCLC
02 Nov 2022
Dog owners ward off asthma against risk allele carriers
Among individuals carrying the 17q12-21 asthma-risk variant rs2305480, owning a dog appears to exert a protective effect against persistent wheeze, a recent study has found.
Dog owners ward off asthma against risk allele carriers
29 Oct 2022
Cemiplimab shows favourable signals as first-, second-line treatment alternative for NSCLC
In the 3-year follow-up of the EMPOWER-Lung 1 study, first-line cemiplimab continued to outdo chemotherapy (CT) in providing survival benefit for patients with advanced non-small-cell lung cancer (NSCLC). Moreover, in the second-line setting (patients with progressive disease [PD]), cemiplimab added to CT provided meaningful and durable objective response rate (ORR) and overall survival (OS) benefit.
Cemiplimab shows favourable signals as first-, second-line treatment alternative for NSCLC
28 Oct 2022
COVID-19 oral antivirals reduce in-hospital mortality and healthcare utilization in real-world setting
Use of molnupiravir or nirmatrelvir/ritonavir in high-risk patients with mild-to-moderate COVID-19 is associated with reduced in-hospital mortality, reduced hospital admissions or readmissions, and potential healthcare cost savings, according to a real-world retrospective cohort study led by researchers from the Chinese University of Hong Kong and the University of Hong Kong.
COVID-19 oral antivirals reduce in-hospital mortality and healthcare utilization in real-world setting
27 Oct 2022
Smell, taste dysfunction post-COVID-19: will these persist?
Olfactory and gustatory** loss/alterations are common COVID-19 symptoms, but recovery is expected in most patients within the first 3 months. However, these dysfunctions may persist in some individuals, according to a reconstructed meta-analysis from Singapore.
Smell, taste dysfunction post-COVID-19: will these persist?
26 Oct 2022
Prophylactic anticoagulation in critical COVID-19: Is full-dose or standard-dose preferred?
A full-dose prophylactic anticoagulation strategy reduced the risk of thrombosis in critically ill patients with COVID-19 who required intensive care unit (ICU)-level care compared with a standard-dose strategy, according to results of the COVID-PACT trial.